Taken together, due to the high survival of patients using durvalumab, it is a novel promising treatment for HNSCC not only in patients with high PD‐L1 profiles but also in patients with low PD‐L1 manifestations.142, 144. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.